Cost-effectiveness of lazertinib as first-line treatment in patients with -mutated advanced lung cancer
Background: Lazertinib demonstrates efficacy similar to that of osimertinib in the first-line treatment of epidermal growth factor receptor ( EGFR )-mutated advanced lung cancer. However, its cost-effectiveness has not yet been evaluated. Objective: To study the cost-effectiveness of lazertinib as a...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2025-01-01
|
| Series: | Therapeutic Advances in Medical Oncology |
| Online Access: | https://doi.org/10.1177/17588359241312143 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|